BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 28336086)

  • 21. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
    Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
    Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stimulating intestinal GIP release reduces food intake and body weight in mice.
    Lewis JE; Nuzzaci D; James-Okoro PP; Montaner M; O'Flaherty E; Darwish T; Hayashi M; Liberles SD; Hornigold D; Naylor J; Baker D; Gribble FM; Reimann F
    Mol Metab; 2024 Jun; 84():101945. PubMed ID: 38653401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C; Xue GF; Lijun C; Feng P; Li D; Li L; Li G; Hölscher C
    Brain Res; 2016 Mar; 1634():1-11. PubMed ID: 26453833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients With Long-QT Syndrome Caused by Impaired
    Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
    Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The incretins: a link between nutrients and well-being.
    Burcelin R
    Br J Nutr; 2005 Apr; 93 Suppl 1():S147-56. PubMed ID: 15877888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice.
    Khan D; Ojo OO; Woodward OR; Lewis JE; Sridhar A; Gribble FM; Reimann F; Flatt PR; Moffett RC
    Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut.
    Morrow NM; Morissette A; Mulvihill EE
    Peptides; 2024 Jun; 176():171200. PubMed ID: 38555054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents.
    Moss CE; Marsh WJ; Parker HE; Ogunnowo-Bada E; Riches CH; Habib AM; Evans ML; Gribble FM; Reimann F
    Diabetologia; 2012 Nov; 55(11):3094-103. PubMed ID: 22872212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GIP and GLP-1, the two incretin hormones: Similarities and differences.
    Seino Y; Fukushima M; Yabe D
    J Diabetes Investig; 2010 Apr; 1(1-2):8-23. PubMed ID: 24843404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expanding incretin universe: from basic biology to clinical translation.
    Drucker DJ; Holst JJ
    Diabetologia; 2023 Oct; 66(10):1765-1779. PubMed ID: 36976349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
    PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.
    Waser B; Beetschen K; Pellegata NS; Reubi JC
    Neuroendocrinology; 2011; 94(4):291-301. PubMed ID: 21893952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
    Ma T; Lu W; Wang Y; Qian P; Tian H; Gao X; Yao W
    Eur J Pharmacol; 2022 Jan; 914():174635. PubMed ID: 34800466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
    Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
    Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
    Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
    Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A; Rosenkilde MM; Gasbjerg LS
    Peptides; 2022 May; 151():170749. PubMed ID: 35065096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Incretin and bone].
    Yamada Y
    Clin Calcium; 2009 Sep; 19(9):1312-7. PubMed ID: 19721203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interplay between bone and incretin hormones: A review.
    Mabilleau G
    Morphologie; 2017 Mar; 101(332):9-18. PubMed ID: 27423214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.